Clinical Trials
42 trialsNCT01804686 2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04063215 2026-01-15
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
Hope Biosciences Research Foundation
Phase 1/2 Completed
NCT03774082 2025-12-11
REACH 5
Novartis
Phase 2 Completed
NCT05951777 2025-09-29
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
Phase 2 Recruiting
NCT06462365 2025-04-15
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
Phase 1 Recruiting
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT02388048 2025-01-29
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT04716075 2025-01-16
ACALLO
Polish Lymphoma Research Group
Phase 2 Completed
NCT00457782 2024-04-25
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT02743351 2023-02-08
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
Phase 1/2 Completed
NCT01991184 2022-06-21
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
Phase 1 Completed
NCT01994382 2022-04-05
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01663766 2021-08-19
Phase I Study of Milatuzumab for Graft Versus Host Disease
Gilead Sciences
Phase 1 Terminated
NCT01578707 2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3 Completed
NCT01490632 2019-09-27
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT01107457 2019-09-24
A Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01240525 2019-02-12
ProT4
University College, London
Phase 2 Unknown
NCT02908347 2019-01-23
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
MetrioPharm AG
Phase 2 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01313689 2018-11-08
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Novartis
Phase 3 Completed
NCT00077922 2018-01-23
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00742144 2017-11-17
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 1 Completed
NCT01163253 2017-06-26
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Terminated
NCT01600053 2016-12-15
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
University of California, San Diego
Phase 2 Terminated
NCT01680991 2016-04-25
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Phase 1 Completed
NCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn
NCT00280241 2016-02-04
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
University of Pittsburgh
Phase 2 Completed
NCT01519089 2015-08-13
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
Phase 3 Completed
NCT00431873 2015-07-01
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Phase 2 Completed
NCT01373983 2014-12-30
ZicBol
University Hospital, Linkoeping
Phase 4 Completed
NCT01276639 2014-09-19
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01309737 2014-09-19
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT00328198 2014-03-13
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Phase 2 Completed
NCT01149668 2013-06-19
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics LLC.
Phase 1 Completed
NCT00078234 2011-11-07
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Genta Incorporated
Phase 1/2 Completed
NCT00825487 2011-10-19
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00103701 2011-04-14
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT00021749 2009-11-13
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
Genta Incorporated
Phase 1/2 Completed
NCT00800943 2008-12-03
CRC005
Chronic Lymphocytic Leukemia Research Consortium
Phase 2 Unknown